Bicycle therapeutics reports recent business progress and fourth quarter and full year 2023 financial results

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided recent corporate updates. “2023 was a pivotal year for our company, during which we achieved significant progress across our nectin-4 and epha2 clinical.
BCYC Ratings Summary
BCYC Quant Ranking